About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Alentis Appoints Mark Pruzanski as CEO

Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology indications, today announced the appointment of Mark Pruzanski, MD, as the company’s new Chief Executive Officer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015571695/en/

Mark Pruzanski, CEO of Alentis Therapeutics

Mark Pruzanski, CEO of Alentis Therapeutics

“We are very pleased to welcome Mark to the company,” said Dr. Luca Santarelli, Chairman of the Board. “He has a proven track record in building and leading successful biotech companies, and I look forward to working with him as we continue to advance our clinical programs and expand our pipeline.”

“I am thrilled to be joining Alentis at this juncture, with key clinical data readouts expected next year for each of our three drug candidates,” said Dr. Pruzanski. “Claudin-1 overexpression was first identified as an important driver of fibrosis in chronic diseases of the liver, kidney and lung. Our lead antibody, lixudebart, selectively targets exposed claudin-1 and has demonstrated initial proof of concept in patients with advanced liver and kidney disease, positioning it as a potential pan-organ antifibrotic therapy. Claudin-1 is also highly expressed in a number of cancers, and we are enthusiastic about the potential of our two lead claudin-1 targeting ADCs currently in Phase 1/2 studies enrolling patients with various solid tumor types.”

Dr. Pruzanski is a physician entrepreneur with more than 30 years of experience in the life sciences industry. Most recently, he served as Chairman and CEO of Versanis Bio where he spearheaded the development of a novel approach to obesity therapy until the company’s acquisition by Eli Lilly and Company. Prior to joining Versanis, he founded and was the longstanding CEO of Intercept Pharmaceuticals, where he successfully steered the molecule obeticholic acid from discovery to a globally marketed product in chronic liver disease. Dr. Pruzanski is currently a member of the Board of Directors of several biotechnology companies and the Biotechnology Innovation Organization (BIO).

I want to thank Dr. Roberto Iacone for his vision and leadership, having served as Alentis’ CEO since 2020,said Dr. Santarelli. “He has been instrumental in building the company from early discovery to a well-capitalized, clinical-stage company with a great team and robust pipeline.

About Alentis Therapeutics

Alentis is a clinical-stage biotechnology company pioneering first-in-class antibodies and antibody-drug conjugates (ADCs) targeting claudin-1 for fibrosis and oncology indications. The company’s lead antibody, lixudebart, demonstrated dose-dependent target engagement and evidence of improved organ function in a Phase 1b study in advanced liver fibrosis and an ongoing Phase 2 study in ANCA-associated vasculitis with renal involvement (RPGN). The company’s lead oncology candidates, ALE.P02 and ALE.P03, are claudin-1 targeted ADCs with a tubulin inhibitor payload and topoisomerase‑I inhibitor payload, respectively. ALE.P02 was granted Fast Track designation by FDA for the treatment of advanced or metastatic claudin-1 expressing squamous cancers, irrespective of the organ of origin. Both ADCs are currently in Phase 1/2 studies enrolling patients with a variety of solid tumor types expressing claudin-1.

Alentis was founded based on ground-breaking research in the laboratory of Prof. Thomas Baumert, MD, at the University of Strasbourg and the French National Institute of Health and Medical Research (Inserm). The company is headquartered in Basel, Switzerland. Visit www.alentis.ch

Alentis appoints Mark Pruzanski CEO. Dr. Pruzanski is a physician entrepreneur with more than 30 years of experience in the life sciences industry. He previously served as CEO of Versanis and was the founder and longstanding CEO of Intercept.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.